

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>BAKER BROS. ADVISORS LP</b>  (Last) (First) (Middle) <b>860 WASHINGTON STREET, 3RD FLOOR</b>  (Street) <b>NEW YORK NY 10014</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>Neoleukin Therapeutics, Inc. [ NLTX ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <b>08/15/2023</b>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication  <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								2,260	D <sup>(1)</sup>	
Common Stock								2,260	D <sup>(2)</sup>	
Common Stock	08/15/2023		P		143,519	A	\$0.6308 <sup>(3)</sup>	463,568	I	See Footnotes <sup>(4)(5)(6)</sup>
Common Stock	08/15/2023		P		1,740,581	A	\$0.6308 <sup>(3)</sup>	5,242,272	I	See Footnotes <sup>(5)(6)(7)</sup>
Common Stock	08/15/2023		P		358	A	\$0.665	463,926	I	See Footnotes <sup>(4)(5)(6)</sup>
Common Stock	08/15/2023		P		4,342	A	\$0.665	5,246,614	I	See Footnotes <sup>(5)(6)(7)</sup>
Common Stock	08/16/2023		P		17,124	A	\$0.6805 <sup>(8)</sup>	481,050	I	See Footnotes <sup>(4)(5)(6)</sup>
Common Stock	08/16/2023		P		207,676	A	\$0.6805 <sup>(8)</sup>	5,454,290	I	See Footnotes <sup>(5)(6)(7)</sup>
Common Stock	08/16/2023		P		366	A	\$0.6828	481,416	I	See Footnotes <sup>(4)(5)(6)</sup>
Common Stock	08/16/2023		P		4,434	A	\$0.6828	5,458,724	I	See Footnotes <sup>(5)(6)(7)</sup>
Common Stock	08/17/2023		P		7,676	A	\$0.6924 <sup>(9)</sup>	489,092	I	See Footnotes <sup>(4)(5)(6)</sup>
Common Stock	08/17/2023		P		93,091	A	\$0.6924 <sup>(9)</sup>	5,551,815	I	See Footnotes <sup>(5)(6)(7)</sup>
Common Stock	08/17/2023		P		5,041	A	\$0.6928 <sup>(10)</sup>	494,133	I	See Footnotes <sup>(4)(5)(6)</sup>
Common Stock	08/17/2023		P		61,134	A	\$0.6928 <sup>(10)</sup>	5,612,949	I	See Footnotes <sup>(5)(6)(7)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code V Transaction Code (Instr. 8)	6A. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	7. Date Exercisable or Expiration Date (Month/Day/Year)	8. Expiration Date and Title	9. Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	10. Price of Derivative Security (Instr. 5)	11. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	12. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	13. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person\*  
667, L.P.  
 \_\_\_\_\_  
 (Last) (First) (Middle)  
860 WASHINGTON STREET, 3RD FLOOR  
 \_\_\_\_\_  
 (Street)  
NEW YORK NY 10014  
 \_\_\_\_\_  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Baker Brothers Life Sciences LP  
 \_\_\_\_\_  
 (Last) (First) (Middle)  
860 WASHINGTON STREET, 3RD FLOOR  
 \_\_\_\_\_  
 (Street)  
NEW YORK NY 10014  
 \_\_\_\_\_  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
BAKER FELIX  
 \_\_\_\_\_  
 (Last) (First) (Middle)  
860 WASHINGTON STREET, 3RD FLOOR  
 \_\_\_\_\_  
 (Street)  
NEW YORK NY 10014  
 \_\_\_\_\_  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
BAKER JULIAN  
 \_\_\_\_\_  
 (Last) (First) (Middle)  
860 WASHINGTON STREET, 3RD FLOOR  
 \_\_\_\_\_  
 (Street)  
NEW YORK NY 10014  
 \_\_\_\_\_  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Baker Bros. Advisors (GP) LLC  
 \_\_\_\_\_  
 (Last) (First) (Middle)  
860 WASHINGTON STREET, 3RD FLOOR  
 \_\_\_\_\_  
 (Street)  
NEW YORK NY 10014  
 \_\_\_\_\_  
 (City) (State) (Zip)

**Explanation of Responses:**

1. Common stock ("Common Stock") of Neoleukin Therapeutics, Inc. (the "Issuer") held directly by Felix J. Baker received from in-kind pro rata distributions without consideration.
2. Common Stock held directly by Julian C. Baker received from in-kind pro rata distributions without consideration.
3. The price reported in Column 4 is a weighted average price. These shares were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from \$0.615 to \$0.68, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
4. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
5. Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
6. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
7. After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
8. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from \$0.6701 to \$0.6991, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
9. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from \$0.6899 to \$0.7100, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
10. The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from \$0.6800 to \$0.7065, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

**Remarks:**

M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP, is a director of Neoleukin Therapeutics, Inc. (the "Issuer"). For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization by virtue of their representation on the board of directors of the Issuer.

By: Baker Bros. Advisors LP,  
Name: Scott L. Lessing, Title: 08/17/2023  
President /s/ Scott L. Lessing  
Baker Bros. Advisors LP,  
Mgmt. Co. and Inv. Adviser to  
667, L.P., pursuant to  
authority granted by Baker  
Biotech Capital, L.P., GP to 08/17/2023  
667, L.P. Name: Scott L.  
Lessing, Title: President /s/  
Scott L. Lessing  
Baker Bros. Advisors LP,  
Mgmt. Co. and Inv. Adviser to  
Baker Brothers Life Sciences,  
L.P., pursuant to authority  
granted by Baker Brothers 08/17/2023  
Life Sciences Capital, L.P., GP  
to Baker Brothers Life  
Sciences, L.P., Name: Scott L.  
Lessing, Title: President /s/  
/s/ Felix J. Baker 08/17/2023  
/s/ Julian C. Baker 08/17/2023  
By: Baker Bros. Advisors  
(GP) LLC, Name: Scott L. 08/17/2023  
Lessing, Title: President /s/  
Scott L. Lessing

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**